Biotech in­dex ris­es above $100 mark for first time in two years

Af­ter a roller coast­er of a two-year ride, the biotech mar­ket’s key stock in­dex, the $XBI, sur­passed the $100 mark on Tues­day, buoy­ing in­vestor op­ti­mism and pro­vid­ing a mo­ment of re­lief for those with mon­ey in the drug de­vel­op­ment in­dus­try.

The 5.7% rise on Tues­day adds to a month­s­long pick­up from the Oc­to­ber dol­drums and an ex­plo­sive da­ta read­out from Viking Ther­a­peu­tics that led to a more than dou­bling of the biotech’s share price as its obe­si­ty drug en­ters Eli Lil­ly and No­vo Nordisk’s back­yard.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER